End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.72 EUR | -1.37% | +2.86% | -75.17% |
04/06 | Acticor: hopes revived in stroke, share price rises | CF |
15/05 | Acticor: 'new perspectives' in stroke treatment | CF |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 48.3 | 74.16 | 11.32 | 11.32 | - |
Enterprise Value (EV) 1 | 39.66 | 75.43 | 16.52 | 22.12 | 5.619 |
P/E ratio | -2.83 x | -4.74 x | -0.61 x | -0.85 x | 0.69 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | -1.07 x | -1.66 x | 0.29 x |
EV / FCF | - | - | -1.07 x | -1.66 x | 0.34 x |
FCF Yield | - | - | -93.2% | -60.1% | 295% |
Price to Book | - | - | -1.29 x | -0.87 x | 3.27 x |
Nbr of stocks (in thousands) | 10,546 | 10,505 | 15,721 | 15,721 | - |
Reference price 2 | 4.580 | 7.060 | 0.7200 | 0.7200 | 0.7200 |
Announcement Date | 30/03/22 | 23/03/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA 1 | - | - | -15.4 | -13.3 | 19.5 |
EBIT 1 | -11.89 | -15.12 | -15.5 | -13.4 | 19.4 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income 1 | -12.61 | -15.88 | -15.5 | -13.4 | 16.4 |
Net margin | - | - | - | - | - |
EPS 2 | -1.620 | -1.490 | -1.180 | -0.8500 | 1.040 |
Free Cash Flow 1 | - | - | -15.4 | -13.3 | 16.6 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | 85.13% |
FCF Conversion (Net income) | - | - | - | - | 101.22% |
Dividend per Share | - | - | - | - | - |
Announcement Date | 30/03/22 | 23/03/23 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt 1 | - | 1.26 | 5.2 | 10.8 | - |
Net Cash position 1 | 8.64 | - | - | - | 5.7 |
Leverage (Debt/EBITDA) | - | - | -0.3377 x | -0.812 x | - |
Free Cash Flow 1 | - | - | -15.4 | -13.3 | 16.6 |
ROE (net income / shareholders' equity) | -198% | - | - | - | 483% |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share 2 | - | - | -0.5600 | -0.8300 | 0.2200 |
Cash Flow per Share 2 | -1.770 | -1.150 | -1.170 | -0.8500 | 1.050 |
Capex 1 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 30/03/22 | 23/03/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-75.17% | 12.28M | |
+16.49% | 122B | |
+21.73% | 116B | |
+22.18% | 27.03B | |
-21.81% | 20.36B | |
-16.89% | 16.43B | |
-18.81% | 15.91B | |
-44.74% | 15.6B | |
+62.72% | 14.94B | |
+3.09% | 13.59B |
- Stock Market
- Equities
- ALACT Stock
- Financials Acticor Biotech SAS